Alector, Inc. (NASDAQ:ALEC) Holdings Trimmed by Marshall Wace LLP

Marshall Wace LLP lowered its position in shares of Alector, Inc. (NASDAQ:ALEC) by 70.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,609 shares of the company’s stock after selling 124,669 shares during the quarter. Marshall Wace LLP owned 0.05% of Alector worth $239,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Alector by 12.0% during the first quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company’s stock valued at $29,574,000 after purchasing an additional 526,037 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Alector by 16.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 922,799 shares of the company’s stock valued at $5,555,000 after purchasing an additional 128,515 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Alector by 32.8% during the second quarter. Acadian Asset Management LLC now owns 590,662 shares of the company’s stock valued at $2,681,000 after purchasing an additional 146,015 shares during the last quarter. Panagora Asset Management Inc. lifted its holdings in shares of Alector by 61.7% during the second quarter. Panagora Asset Management Inc. now owns 355,318 shares of the company’s stock valued at $1,613,000 after purchasing an additional 135,614 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Alector by 21.5% during the second quarter. Bank of New York Mellon Corp now owns 279,938 shares of the company’s stock valued at $1,271,000 after purchasing an additional 49,625 shares during the last quarter. 85.83% of the stock is owned by hedge funds and other institutional investors.

Alector Trading Up 5.5 %

Shares of Alector stock opened at $4.80 on Friday. Alector, Inc. has a 1 year low of $3.66 and a 1 year high of $8.90. The stock has a 50-day moving average price of $5.11 and a 200 day moving average price of $5.22. The company has a market cap of $467.14 million, a P/E ratio of -2.67 and a beta of 0.68.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.09. Alector had a negative return on equity of 102.63% and a negative net margin of 290.66%. The company had revenue of $15.08 million during the quarter, compared to the consensus estimate of $16.04 million. During the same period last year, the business earned $0.02 EPS. On average, equities analysts forecast that Alector, Inc. will post -1.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ALEC has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Alector in a research note on Thursday, June 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a research note on Tuesday, September 17th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.75.

Insider Transactions at Alector

In other news, insider Sara Kenkare-Mitra sold 13,926 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $67,958.88. Following the completion of the sale, the insider now directly owns 291,715 shares of the company’s stock, valued at $1,423,569.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Arnon Rosenthal sold 26,499 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $129,315.12. Following the transaction, the chief executive officer now owns 1,948,746 shares of the company’s stock, valued at approximately $9,509,880.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sara Kenkare-Mitra sold 13,926 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $67,958.88. Following the transaction, the insider now directly owns 291,715 shares in the company, valued at approximately $1,423,569.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,222 shares of company stock valued at $286,013 in the last three months. Corporate insiders own 9.10% of the company’s stock.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.